Linsitinib showed significant efficacy in reducing proptosis in TED patients, with a 52% responder rate at 150mg BID. The ...
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical ...
Andrew G. Lee, MD, and Andrew Carey, MD, return for this latest episode of the NeuroOp Guru to discuss whether a dead nerve ...
InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...
The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...
AI-based screening for pediatric DRD is more cost-effective and increases screening rates compared to traditional ECP methods ...
The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in ...
Panelists discuss how successful implementation of the port delivery system requires careful attention to surgical technique ...
New features include simultaneous calculation for both eyes, access to toric and non-toric results, and improved theater view design.
RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, secured Series A financing of $86 million ...
Study sees a positive association between the dietary inflammatory index (DII) and non-refractive visual impairment among US ...